A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer.
- Author:
Bong Gun SEO
1
;
Sung Yong OH
;
Dong Mee LEE
;
Hyun Seung YOO
;
Suee LEE
;
Seong Geun KIM
;
Sung Hyun KIM
;
Hyuk Chan KWON
;
Hyo Jin KIM
Author Information
1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. kimhj@dau.ac.kr
- Publication Type:Original Article
- Keywords:
Paclitaxel;
Cisplatin;
Salvage;
Advanced gastric cancer
- MeSH:
Anemia;
Cisplatin*;
Drug Therapy;
Drug Therapy, Combination;
Humans;
Neutropenia;
Paclitaxel*;
Salvage Therapy*;
Stomach Neoplasms*;
Survival Rate
- From:Cancer Research and Treatment
2007;39(1):6-9
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate the therapeutic activity and safety of paclitaxel and cisplatin combination chemotherapy in patients with advanced or metastatic gastric cancers that are unresponsive to primary chemotherapy. MATERIALS AND METHODS: Advanced or metastatic gastric cancer patients unresponsive to first line chemotherapy were entered into this trial. The treatment regimen consisted of paclitaxel, 175 mg/m(2) by 3-hour infusion on day 1, and cisplatin, 60 mg/m(2) by 1 hour infusion on day 1, with the treatment repeated every 3 weeks. RESULTS: 37 patients were entered in this study, with 32 fully evaluable for response. 4 (13%), 13 (40%) and 15 (47%) patients achieved a partial response, stable disease and progressed, respectively. The median time to progression was 4.0 months (95% CI: 2.0~6.0 months), and the median overall survival was 12.6 months (95% CI: 5.5~19.7 months), with a 1-year survival rate of 54%. Of a total of 135 cycles of chemotherapy, grades 3 and 4 hematological toxicities were neutropenia (14%) and anemia (3%). Grade > or =2 neuropathy was observed in 6 patients (17%). CONCLUSION: The combination of paclitaxel and cisplatin is an effective and tolerable salvage treatment modality for advanced gastric cancer.
